New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:46 EDTKPTIKaryopharm announces initiation of Selinexor Phase 2 study
Karyopharm Therapeutics announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor, or KPT-330, in patients with metastatic hormone-refractory prostate cancer. The study, referred to as the SHIP, or Selinexor in Hormone Refractory Indications in Prostate Cancer, study, is led by Drs. Christopher Logothetis and John Araujo of the M.D. Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
07:15 EDTKPTIKaryopharm expects existing cash will fund R&D programs into 2018
Based on current operating plans, Karyopharm expects that its existing cash and cash equivalents will fund its research and development programs and operations into 2018, including moving registration-directed clinical studies to their next data inflection points. Karyopharm expects to end 2015 with greater than $200M in cash, cash equivalents and investments.
07:13 EDTKPTIKaryopharm reports Q4 EPS (79c), consensus (65c)
Reports Q4 revenue $16,000, consensus $40,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use